Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer
Stopped early · Phase 1/Phase 2
Conditions studied: Recurrent Renal Cell Cancer, Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
In brief
This phase I/randomized phase II trial is studying the side effects and best dose of bevacizumab and to see how well it works when given together with or without MEDI-522 in treating patients with unresectable or metastatic kidney cancer. Monoclonal antibodies, such as bevacizumab and MEDI-522, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab and MEDI-522 may also stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether bevacizumab is more effective when given together with or without MEDI-522 in treating kidney cancer.
Key facts
- Study ID
- NCT00684996
- Run by
- National Cancer Institute (NCI)
- People needed
- 5
- Starts
- 2008-06-01
- Expected to finish
- 2010-10-01
- Last updated by the study team
- 2014-05-15
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Fremont - Rideout Cancer Center — Marysville, California, United States
- University of California at Davis Cancer Center — Sacramento, California, United States
- University of Michigan — Ann Arbor, Michigan, United States
- Novant Health Presbyterian Medical Center — Charlotte, North Carolina, United States
- SWOG — Portland, Oregon, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.